A Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of YN001 in Patients With Atherosclerotic Cardiovascular and Cerebrovascular Diseases and Erectile Dysfunction
Latest Information Update: 05 Jan 2026
At a glance
- Drugs YN 001 (Primary)
- Indications Atherosclerosis; Cardiovascular disorders; Erectile dysfunction
- Focus Therapeutic Use
- Sponsors Beijing Inno Medicine
Most Recent Events
- 05 Jan 2026 New trial record